Gan & Lee’s Rapilin™ 30 Officially Debuts as the Malaysia’s First Insulin Aspart 30 Biosimilar

BEIJING, China, February 14, 2026 —— Gan & Lee Pharmaceuticals. (hereinafter referred to as "Gan & Lee", Stock Code: 603087.SH) is pleased to announce the official launch of its self-developed insulin aspart 30 injection (Trade Name: Rapilin™ 30) at the 1st Biosimilar Insulin Analogue Forum held in Kuala Lumpur. This milestone marks the product's debut as the Malaysia's first insulin aspart 30 biosimilar. Organized by Gan & Lee's local strategic partner and strongly supported by the Malaysian Medical Association (MMA), the forum served as a premier professional exchange platform for diabetes diagnosis and treatment in the region. The launch represents a significant milestone in the deep collaboration between Gan & Lee and its local partner, signaling the successful entry of Gan & Lee's third-generation insulin products into the Malaysian market. As a major academic event in Malaysia's endocrine field, the forum convened numerous authoritative clinical experts. Discussions focused on the application value of biosimilar within the Malaysian public health system, clinical adaptability, and future development prospects, providing expert insights and enhancing local diabetes care standards. During the session, Dr. Masni Binti Mohamad, Senior Consultant Endocrinologist at Putrajaya Hospital, shared insights drawing on her extensive clinical experience. She systematically discussed medication strategies, clinical benefits, and case studies regarding the transition from second-generation human insulin to third-generation insulin analogues, offering essential guidance for clinicians on rational drug use. The official launch of Rapilin ™ 30 will effectively accelerate the transition and upgrade of clinical treatment in Malaysia from second-generation human insulin to third-generation insulin analogues. With its core advantages of stable efficacy and well-proven safety, Rapilin ™ 30 is set to meet the local demand for high-quality diabetes medications and enhance the comprehensive management capabilities of Malaysia's public health system. Coinciding with the milestone of the "Golden 50 Years" of China-Malaysia relations, the successful landing of Rapilin ™ 30 is not only a key breakthrough in Gan & Lee's international strategy but also a landmark achievement in pragmatic medical and health cooperation between the two nations. It injects new vitality into bilateral trade and livelihood collaboration. Moving forward, Gan & Lee will leverage this launch to further deepen its presence in the Malaysian market. The company remains committed to strengthening communication and collaboration with the local medical community, industry associations, and partner. Simultaneously, Gan & Lee will continue to advance its globalization strategy, accelerating the global commercialization of its core products to serve patients worldwide with superior biopharmaceutical solutions. About Gan & Lee Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company and the first in China to master industrial-scale manufacturing technologies for recombinant insulin analogs. The Company has established a comprehensive insulin research and development pipeline. Currently, Gan & Lee offers six core insulin products, including five insulin analogs: insulin glargine injection (Basalin ® ; EU brand name Ondibta ® ), insulin lispro injection (Prandilin ® ; EU brand name: Bysumlog ® ), insulin aspart injection (Rapilin ® ; EU brand name: Dazparda ® ), premixed insulin lispro protamine suspension injection (25R) (Prandilin ® 25), and insulin aspart 30 injection (Rapilin ® 30); as well as one human insulin product, premixed human insulin protamine suspension injection (30R) (Similin ® 30), together with related delivery devices. These products cover the long-acting, rapid-acting, and premixed insulins. In China's second round of national volume-based procurement for insulin, Gan & Lee ranked first among selected companies by contracted volume for insulin analogs, further strengthening its domestic market position. In parallel, the Company continues to advance its international expansion. Insulin glargine injection has received marketing authorization from the European Commission (EC), while for insulin lispro injection and insulin aspart injection, it has received the positive opinion from CHMP of EMA. Gan & Lee is steadily progressing toward its goal of becoming a key global participant in the field of metabolic diseases. Looking forward, Gan & Lee is committed to achieving comprehensive coverage across the diabetes treatment landscape and further enhancing its competitive position in this therapeutic area. The Company will also actively pursue the development of innovative chemical drugs and biologics, with a strategic focus on metabolic diseases, cardiovascular diseases, and other therapeutic areas.

The release as fetched from its publisher. ganlee.com ↗